Drug Trial Radar · NCT07662811
SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
396
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Shanghai Chest HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer
Conditions
- Non-Small Cell Lung Cancer
Interventions
SYHX2011Drug
SYHX2011:260 mg/m\^2, IV/30 ± 3 minutes(day1)
CarboplatinDrug
Carboplatin: AUC 5 mg/mL/min, IV/30\~60 minutes(day1)
EnlonstobartDrug
Enlonstobart: 360 mg, IV/60 minutes(day1)
Nab-PaclitaxelDrug
Nab-Paclitaxel: 260 mg/m\^2, IV/30 ± 3 minutes(day1)
CarboplatinDrug
Carboplatin: AUC 5 mg/mL/min, IV/30\~60 minutes(day1)
TislelizumabDrug
Tislelizumab: 200 mg, IV/60 minutes(day1)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) for phase IITime frame: Throughout the study period, an average of 3 years
- Progression Free Survival (PFS) for phase IIITime frame: Throughout the study period, an average of 3 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.